Designed and developed to be the perfect balance between innovation and coagulation expertise, Stago creates a new range of coagulation instruments: sthemO.

wo new analyzers emerged: sthemO 301 and sthemO 201.

To improve the health of as many people as possible, we are happy to share the renew of our coagulationStago_sthemO_301&201 product offer:

sthemO 301 is dedicated to medium to large laboratories. This fully-automated coagulation analyzer can easily step in automated tracks.
sthemO 201 is a bench-top analyzer for smaller laboratories and guarantees efficiency and analytical performances – just like higher range instruments.
To optimize these two new systems, Stago also shaped new eSolutions in a multi-products offer called sthemE. It’s user-friendly, simple and most of all, brings Stago expertise at hands.
Good news! No need to wait for more information about sthemO range.

AliveDx held its first Golden Partners Meeting

In November 5, 2023, AliveDx held its first Golden Partners Meeting at its headquarters in Eysins, Switzerland. For four consecutive days, our Golden Partners from all around the world engaged with our management team and representatives from our commercial, regulatory, and technical teams. Our Golden Partners attended presentations, brainstorming sessions, and visited our manufacturing facilities. They also enjoyed the first-hand experience of operating our MosaiQ instrument – our multimodal, multiplex testing platform.

Our Golden Partners came from the Middle East, Asia, Europe, and the Pacific. This international group of more than thirty people shares the same enthusiasm, drive, and energy to innovate for life and transform patient care. By focusing on patients and customers together, we will all be able to advance and take center stage in the drive to enhance and accelerate diagnostic pathways.

“It is a privilege for us to collaborate with such devoted expert partners. Our short days together were incredibly motivating,” said Manuel O. Méndez, AliveDx’s CEO. “It was really inspiring to see them leave our offices with such a strong desire to create value for the medical community and to improve patients’ lives.”

Cases of Mycoplasma pneumoniae infection continue to rise worldwide, especially among children. We’re committed to supporting the global hashtag#healthcare community with our QIAstat-Dx Respiratory SARS-CoV-2 Panel.

Our test accurately detects over 20 viral and bacterial targets, enabling the detection of Mycoplasma pneumoniae and associated co-infections.
QIAstat-Dx delivers highly sensitive and specific results in about an hour, allowing healthcare professionals to promptly determine appropriate treatments.
Our user-friendly system provides easy-to-view cycle threshold values and amplification curves, setting it apart from “black box” techniques that only yield binary positive or negative results.